Giuseppe Trifirò

Giuseppe Trifirò

Auto-generated profile, based on publicly available information

Giuseppe Trifirò

Nuclear Medicine Unit, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2011 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Oreste D. GentiliniOreste D. Gentilini
Oreste D. Gentilini
PVPAOLO VERONESI
PAOLO VERONESI
EBEdoardo Botteri
Edoardo Botteri
FSFiammetta Soggiu
Fiammetta Soggiu
GTGiuseppe Trifirò
Giuseppe Trifirò
ALAlberto Luini
Alberto Luini

31 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Laura EvangelistaLaura Evangelista
Laura Evangelista
ABAndrea Bianchi
Andrea Bianchi
ANNOVAZZI ALESSIOANNOVAZZI ALESSIO
ANNOVAZZI ALESSIO
RSRosa Sciuto
Rosa Sciuto
STSilvia Di Traglia
Silvia Di Traglia
MRMaria Luisa De Rimini
Maria Luisa De Rimini
AIM: To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors. METHODS: Data recorded in a multicenter (n = 17), retrospective database between March and November 2021 were analyzed. The sample included patients with a confirmed diagnosis of a solid tumor who underwent serial [18F]FDG PET/CT (before and after one or more cycles of immunotherapy), who were >18 years of age, and had a follow-up of at least 12 months after their first PET/CT scan. Patients enrolled in clinical trials or without a confirmed diagnosis of cancer were excluded. The authors classified cases as having a complete or partial metabolic response to immunotherapy, or stable or progressive metabolic disease, based on a visual and semiquantitative analysis according to the EORTC criteria. Clinical response to immunotherapy was assessed at much the same time points as the serial PET scans, and both the obtained responses were compared. RESULTS: The study concerned 311 patients (median age: 67; range: 31–89 years) in all. The most common neoplasm was lung cancer (56.9%), followed by malignant melanoma (32.5%). Nivolumab was administered in 46.3%, and pembrolizumab in 40.5% of patients. Baseline PET and a first PET scan performed at a median 3 months after starting immunotherapy were available for all 311 patients, while subsequent PET scans were obtained after a median 6, 12, 16, and 21 months for 199 (64%), 102 (33%), 46 (15%), and 23 (7%) patients, respectively. Clinical response to therapy was recorded at around the same time points after starting immunotherapy for 252 (81%), 173 (56%), 85 (27%), 40 (13%), and 22 (7%) patients, respectively. After a median 18 (1–137) months, 113 (36.3%) patients had died. On Kaplan–Meier analysis, metabolic responders on the first two serial PET scans showed a better prognosis than non-responders, while clinical response became prognostically informative from the second assessment after starting immunotherapy onwards. CONCLUSIONS: [18F]FDG PET/CT could have a role in the assessment of response to immunotherapy in patients with some solid tumors. It can provide prognostic information and thus contribute to a patient’s appropriate treatment. Prospective randomized controlled trials are mandatory.

26 March 2019 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
EQErica Quaquarini
Erica Quaquarini
DDD. D’aMbrosio
D. D’aMbrosio
FSF. Sottotetti
F. Sottotetti
FGFrancesca Gallivanone
Francesca Gallivanone
MHM. Hodolic
M. Hodolic
GTG. Trifirò
G. Trifirò
Background and Aim. The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of 18F-fluorocholine (18F-FCH) positron emission tomography (PET) parameters in mCRPC. Materials and Methods. Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent 18F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment 18F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUVmax, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body 18F-FCH PET indices were performed, and p<0.05 was considered as significant. Results. Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and 18F-FCH PET parameters were defined probably due to the small sample size. Conclusions. Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of 18F-FCH PET/CT imaging in clinical decision-making.

1 January 2010 in ecancermedicalscience
Verified
Journal Article
Open access
AMA Mallia
A Mallia
LTLl Travaini
Ll Travaini
GTG Trifiro
G Trifiro
GPG Paganelli
G Paganelli
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide

24 July 2024 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
PDF file
DCDavide Comolli
Davide Comolli
SRSimone Regalbuto
Simone Regalbuto
SASebastiano Arceri
Sebastiano Arceri
GTGiuseppe Trifirò
Giuseppe Trifirò
ACAlessandra Calculli
Alessandra Calculli
Antonio PisaniAntonio Pisani
Antonio Pisani
Tremor and Other Hyperkinetic Movements (TOHM) [ISSN: 2160-8288], a fully open access peer-reviewed journal, publishes clinical and scientific papers on tremor and hyperkinetic movements. TOHM is indexed in PubMed and PubMed Central. In contrast to other publications focusing on disorders of hypokinesia (i.e., mainly Parkinson’s disease), TOHM emphasizes the hyperkinetic movements, giving center stage to clinical observations and research in this area. Papers on Parkinson’s disease and related disorders will be considered if they relate to the hyperkinetic features of these diseases (e.g., tremor, dystonia, dyskinesias). The average turnaround time from submission to first decision is roughly 24 days (~3.5 weeks). The average turnaround time from acceptance to publication is 18 days (~2.5 weeks) with a median of 14 days (2 weeks). Tremor and Other Hyperkinetic Movements is indexed with the Web of Science Emerging Sources Citation Index. As of 2024, Tremor has a Journal Impact Factor of 2.5.